Literature DB >> 2139671

Meningococcemia and purpura fulminans in adults: acute deficiencies of proteins C and S and early treatment with antithrombin III concentrates.

F Fourrier1, P Lestavel, C Chopin, A Marey, J Goudemand, A Rime, J Mangalaboyi.   

Abstract

It has been recently suggested that an acquired deficiency of proteins C and S could contribute to the pathogenesis of meningococcemic purpura fulminans (PF) in children. Our study was designed to measure the levels of antithrombin III (AT III), protein C, and protein S during adult PF and to determine the effects of an early infusion of high doses of AT III concentrates on clinical and biological alterations of PF. We studied five consecutive adult patients with meningococcemia (type B) and PF. The levels of AT III, protein C (antigen and activity), and protein S (total and free) were measured at admission and 24 h and 1 month later. The treatment included in each case: amoxycillin, dobutamine and high doses of AT III concentrates. All patients survived and were discharged without any sequelae. At admission, biological data were consistent with severely depressed protein C and protein S levels and moderately decreased AT III levels, without any discrepancy between protein C antigen and activity. After 24 h, AT III and protein S levels were within normal ranges, whereas protein C levels were still depressed. These data are consistent with the theory of a particular imbalance in the anticoagulant systems during meningococcemic PF, contrasting with the usual findings observed during septic disseminated intravascular coagulation. The possibility must be considered that high doses of one anticoagulant (AT III concentrates) could compensate for the acute decrease in the other (protein C system).

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2139671     DOI: 10.1007/bf02575306

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  22 in total

Review 1.  Recognition, treatment and complications of meningococcal disease.

Authors:  F A Riordan; A P Thomson
Journal:  Paediatr Drugs       Date:  1999 Oct-Dec       Impact factor: 3.022

Review 2.  Pathophysiology of meningococcal meningitis and septicaemia.

Authors:  N Pathan; S N Faust; M Levin
Journal:  Arch Dis Child       Date:  2003-07       Impact factor: 3.791

Review 3.  Emerging therapies in severe sepsis.

Authors:  S J Finney; T W Evans
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

Review 4.  [Microcirculation and hemostasis in inflammatory processes. Modulation by administration of physiologic protease inhibitors as a therapeutic approach].

Authors:  B Leithäuser; F R Matthias
Journal:  Med Klin (Munich)       Date:  1997-07-15

5.  Four-extremity amputation following disseminated intravascular coagulation and purpura fulminans.

Authors:  Umar F Bhatti; Aaron M Williams; Krishnan Raghavendran; Patrick E Georgoff
Journal:  BMJ Case Rep       Date:  2019-03-20

Review 6.  Update on meningococcal disease with emphasis on pathogenesis and clinical management.

Authors:  M van Deuren; P Brandtzaeg; J W van der Meer
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

7.  Proteolytic activity and fatal gram-negative sepsis in burned mice: effect of exogenous proteinase inhibition.

Authors:  A N Neely; R G Miller; I A Holder
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

8.  Use of antithrombin III in critical patients.

Authors:  J M Díaz-Cremades; R Lorenzo; M Sánchez; M J Moreno; M J Alsar; J M Bosch; L Fajardo; D González; D Guerrero
Journal:  Intensive Care Med       Date:  1994-11       Impact factor: 17.440

Review 9.  Rapid recovery of acquired purpura fulminans in a patient with familial C4bBP deficiency.

Authors:  F G Lemesle; J C Gris; J F Schwed; C Arich
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

10.  Bilateral massive adrenal hemorrhage due to sepsis: report of two cases.

Authors:  A Piccioli; G Chini; M Mannelli; M Serio
Journal:  J Endocrinol Invest       Date:  1994-11       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.